Concerning neuroprotective therapy for Parkinson's disease.
Studying potential neuroprotective therapy for Parkinson's disease is conceptually problematic because of the heterogenous nature of the Parkinson's syndrome and complexities in operational definitions for neuroprotection. The current literature concerning neuroprotection provides no convincing evidence of any treatment as definitively neuroprotective in Parkinson's disease. Recent clinical trials and novel trial designs are reviewed that may identify meaningful therapy, resulting in maintenance of neurological function and quality of life for persons with Parkinson's disease.
Uitti
R J
RJ
Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA. uitti.ryan@mayo.edu
Wszolek
Z K
ZK
D002986:Clinical Trials as Topic; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology
D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline